Compare ARL & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARL | PROF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Building operators | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.0M | 230.4M |
| IPO Year | N/A | N/A |
| Metric | ARL | PROF |
|---|---|---|
| Price | $17.15 | $6.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 1.9K | ★ 177.4K |
| Earning Date | 03-19-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $49,060,000.00 | $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | N/A | $113.06 |
| P/E Ratio | $48.09 | ★ N/A |
| Revenue Growth | N/A | ★ 67.94 |
| 52 Week Low | $9.43 | $3.76 |
| 52 Week High | $20.00 | $8.95 |
| Indicator | ARL | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 41.03 |
| Support Level | $17.10 | $6.00 |
| Resistance Level | $18.00 | $6.82 |
| Average True Range (ATR) | 0.60 | 0.53 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 28.57 | 27.91 |
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.